Pruritus Definition and Management

Introduction to Pruritus

• Pruritus is defined as the sensation that is relieved by scratching the skin, commonly known as itching, and is a distressing symptom that significantly impairs quality of life similar to chronic pain 1, 2
• The British Journal of Dermatology guidelines suggest that pruritus is perhaps the most common presenting symptom in dermatology, affecting approximately 8% of all cases as generalized pruritus of unknown origin (GPUO) 3, 4

Pathophysiology of Pruritus

• It occurs when somatosensory neurons that carry the sense of touch, pain, and itch are activated by tissue damage or inflammation 1
• Pain and itch sensations arise from activation of primary sensory neurons, but are transduced by distinct subpopulations of sensory neurons and spinal afferent pathways, though there may be "cross-talk" between these neuronal circuits 1
• Various centers within the central nervous system are implicated in chronic pruritus perception, including signal transducer and activator of transcription 3, lipocalin-2-mediated signaling in astrocytes, and GABA A receptor activation in the central nucleus of the amygdala 1

Classification and Causes of Pruritus

• Pruritus can be classified into several categories, including pruritus with associated underlying dermatosis 1 and pruritus with no underlying dermatosis, such as secondary pruritus due to underlying systemic disorder 3 and generalized pruritus of unknown origin (GPUO) 1
• Disorders of iron metabolism (both deficiency and overload) can cause pruritus 1, 2
• Uremia and renal insufficiency can also cause pruritus 3
• Hepatic disease, especially cholestasis, is another cause of pruritus 3
• Malignancy (Hodgkin's lymphoma, polycythemia vera, solid tumors) can cause pruritus 3
• Hematological disorders, infection (including HIV), endocrine disease (thyroid disorders, diabetes), neurological disorders, and psychological and emotional factors can also contribute to pruritus 3, 5
• Adverse drug reactions (particularly opioid-induced pruritus) and heart failure are additional causes of pruritus 3
• Pregnancy and pruritus of elderly skin are also associated with pruritus 3
• Pruritus of unknown origin (GPUO) is a common condition 3

Diagnostic Approach to Pruritus

• For generalized pruritus without rash, a thorough evaluation for systemic causes should include ferritin levels (iron studies) 1, 2
• Iron deficiency is a common cause of generalized pruritus, with studies showing that iron replacement can lead to complete cessation of pruritus shortly after treatment begins 2

Management of Pruritus

• Iron replacement therapy is recommended for iron deficiency 1, 2
• Psychotropic drugs and psychological therapy may be used to treat psychogenic pruritus 5
• The British Journal of Dermatology guidelines suggest that treating the underlying disease is essential for managing systemic conditions that cause pruritus 1, 2, 3, 5

Impact of Pruritus on Quality of Life

• Chronic pruritus significantly impairs quality of life, similar to chronic pain 1, 2
• Psychological factors can trigger or worsen pruritus, including stress, emotional excitation, and cognitive factors 5
• A nursing program called "Coping with Itch" has shown improvements in itch-related coping, though not necessarily in itch intensity 5

Systemic Diseases That Cause Pruritus

Diagnostic Recommendations

• The British Association of Dermatologists recommends initial investigations for all patients with chronic generalized pruritus without rash, including full blood count and ferritin levels, liver function tests, and urea and electrolytes 6
• Liver function tests should be performed in all cases of generalized pruritus without rash, as cholestatic liver disease is a major cause of generalized pruritus 6
• Urea and electrolytes should be part of the initial investigation in all patients with unexplained pruritus, as chronic kidney disease and uremia are well-established causes of generalized pruritus 6
• Routine endocrine testing is not recommended unless clinical features specifically suggest endocrinopathy, but thyroid function tests should be considered if clinical features suggest thyroid disease 6
• JAK2 V617F mutation analysis should be considered if polycythemia vera is suspected, as it presents characteristically with aquagenic pruritus 6
• HIV and hepatitis serology should be considered with appropriate travel or risk history, as HIV infection and hepatitis A, B, and C can cause generalized pruritus 6
• Skin biopsy should be considered for persistent unexplained pruritus to evaluate for cutaneous lymphoma or small fiber neuropathy 6

Management of Pruritus

Introduction to Pruritus Management

• The British Association of Dermatologists recommends obtaining liver function tests, bilirubin, and serum bile acids immediately in the outpatient setting for patients with pruritus without rash, unless they develop signs of systemic instability 7, 8
• Pruritus without rash is rarely an emergency unless accompanied by systemic signs of anaphylaxis, severe hepatic failure, or hemodynamic instability, according to the British Journal of Dermatology 7, 9

Diagnostic Approach

• The American Journal of Obstetrics and Gynecology suggests that both celecoxib and rosuvastatin can cause hepatotoxicity, making drug-induced cholestatic liver disease a key consideration that requires laboratory confirmation 10
• The British Journal of Dermatology recommends the following initial panel for generalized pruritus without rash: liver function tests, total bilirubin, serum bile acids, complete blood count with differential, ferritin level, urea and electrolytes, and antimitochondrial antibodies 7, 8

Differential Diagnosis

• The American Journal of Respiratory and Critical Care Medicine notes that rosuvastatin causes cholestatic hepatitis in 1.1% of patients, with pruritus as a cardinal symptom 10
• The British Journal of Dermatology states that primary biliary cholangitis should be considered if antimitochondrial antibodies are present 7

Management

• The British Journal of Dermatology recommends discontinuing rosuvastatin immediately if it is suspected to be the cause of cholestatic pruritus 7, 8
• The British Journal of Dermatology suggests using emollients and moisturizers as first-line treatment for all pruritus, and non-sedating antihistamines for symptomatic relief 7, 11
• The British Journal of Dermatology recommends rifampin 150 mg twice daily as first-line treatment for hepatic pruritus, and cholestyramine 9 g daily as second-line treatment 7

Referral and Escalation

• The American Journal of Obstetrics and Gynecology recommends referring patients to hepatology if significant hepatic impairment or persistent elevation is present 9
• The British Journal of Dermatology suggests referring patients to nephrology for dialysis optimization and management if creatinine is elevated 7, 8
• The American Journal of Obstetrics and Gynecology recommends sending patients to the ER immediately if they develop hypotension, tachycardia, or respiratory distress, severe abdominal pain with jaundice, altered mental status, or rash with fever and mucosal involvement 9

Diagnosis and Management of Generalized Pruritus Without Rash

Initial Diagnostic Workup and Management

• The British Association of Dermatologists recommends a full blood count with differential, ferritin levels, liver function tests, and total bilirubin as part of the initial diagnostic workup for chronic generalized pruritus without rash, but does not specify the inclusion of IgE measurement in this context, however, other sources suggest that drug-induced pruritus should be considered, with 12.5% of drug reactions presenting with pruritus without rash 12, 13

Systemic Causes of Pruritus

• Iron deficiency is a treatable cause of generalized pruritus, with iron replacement leading to complete cessation of pruritus shortly after treatment begins, although the exact citation for this is not provided, other sources indicate that drug-induced pruritus is a significant concern, with a complete medication history necessary for diagnosis 12, 13
• Cholestatic liver disease is a major cause of generalized pruritus, with pruritus predominantly affecting palms and soles, worsening at night, and requiring bile acid measurement for diagnosis, but no specific citation is provided for this, however, drug-induced pruritus is a common issue, with 12.5% of drug reactions presenting with pruritus without rash 12, 13

Diagnostic Approach to Pruritus Without Rash

Initial Management and Treatment

• The American Society of Clinical Oncology recommends beginning symptomatic treatment immediately while diagnostic evaluation proceeds, including the use of emollients, moisturizers, topical anti-itch remedies, and non-sedating antihistamines for symptomatic relief 14
• The use of refrigerated menthol and pramoxine for symptomatic relief is recommended, as stated in the Journal of Clinical Oncology 14
• For severe refractory pruritus, consideration of gabapentin, pregabalin, aprepitant, or dupilumab is recommended, according to the Journal of Clinical Oncology 14

Diagnostic Approach and Management of Generalized Pruritus

Key Diagnostic Features

• The American College of Obstetricians and Gynecologists suggests that intrahepatic cholestasis of pregnancy (ICP) causes generalized itching predominantly affecting palms and soles, worse at night, and is generally not associated with a rash 15
• The British Association of Dermatologists recommends considering iron deficiency as a common, treatable cause of generalized pruritus without rash 16

Immediate Diagnostic Workup

• The British Association of Dermatologists recommends ordering a complete blood count with differential, ferritin levels, liver function tests, total bilirubin, and serum bile acids as part of the initial diagnostic workup for generalized pruritus 16

Critical History and Physical Examination Elements

• The American College of Obstetricians and Gynecologists suggests that new-onset pruritus in the second half of pregnancy suggests ICP, and a thorough history and physical examination are essential for diagnosis 15
• The British Association of Dermatologists recommends focusing on the onset timing, distribution, and associated symptoms to guide the diagnostic workup for generalized pruritus 16

Immediate Symptomatic Treatment

• The British Association of Dermatologists recommends using emollients and moisturizers as first-line treatment for all pruritus, while awaiting diagnostic results 16
• The American Society of Clinical Oncology suggests using gabapentin 300-1200 mg daily in divided doses for severe refractory pruritus 17

Condition-Specific Management

• The American College of Obstetricians and Gynecologists recommends rifampin 150 mg twice daily as first-line treatment for hepatic pruritus, and cholestyramine 9 g daily as second-line treatment 15

When to Escalate Care

• The British Association of Dermatologists recommends referring to dermatology if rash persists beyond 2 weeks or diagnosis remains uncertain, and to hepatology if significant hepatic impairment or persistent elevation of liver enzymes is present 16
• The American College of Obstetricians and Gynecologists suggests referring to emergency department immediately if severe abdominal pain with jaundice occurs, or altered mental status develops 15

Management of Severe Pruritus Worsening with Salt Intake

Introduction to Pruritus Management

• For patients with severe pruritus that worsens with increased salt intake, the British Journal of Dermatology recommends immediately restricting dietary sodium to less than 2 grams per day and investigating for underlying kidney disease, liver disease, or heart failure, as salt-sensitive pruritus strongly suggests fluid retention and systemic disease 18, 19

Diagnostic Workup

• The American Academy of Dermatology suggests ordering a complete blood count with ferritin levels, as iron deficiency causes generalized pruritus and responds completely to iron replacement 18, 20
• The British Journal of Dermatology recommends ordering a comprehensive metabolic panel, including urea, creatinine, and electrolytes, as uremic pruritus from chronic kidney disease is common and salt intake worsens fluid retention 18, 19, 21
• The European Association for the Study of the Liver suggests ordering liver function tests, total bilirubin, and serum bile acids, as cholestatic liver disease causes severe pruritus, particularly affecting palms and soles, worse at night 18, 19

Dietary and Lifestyle Modifications

• The American Heart Association recommends limiting dietary sodium to less than 2 grams daily, as this directly addresses the salt-triggered worsening and reduces fluid retention in kidney, liver, or heart disease 18, 19, 21
• The British Journal of Dermatology suggests applying emollients at least twice daily, as xerosis (dry skin) is universal in chronic kidney disease and lowers the threshold for pruritus 18, 19, 21

Treatment Algorithm

• For uremic pruritus, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend optimizing dialysis adequacy, ensuring Kt/V ≥1.6, as adequate dialysis relieves pruritus in 40% of patients 18, 21
• For hepatic/cholestatic pruritus, the European Association for the Study of the Liver recommends rifampicin 150 mg twice daily as first-line treatment, with a strength of recommendation A 18, 19
• For iron deficiency, the American Academy of Dermatology recommends iron replacement therapy, which leads to complete cessation of pruritus shortly after treatment begins, with a strength of recommendation C 18, 20

Symptomatic Treatment

• The British Journal of Dermatology suggests using broadband UVB phototherapy as a first-line pharmacologic therapy for uremic pruritus, with a strength of recommendation A 18, 19
• The American Academy of Dermatology recommends gabapentin 300-1200 mg daily, with a strength of recommendation D, for uremic pruritus 18, 19

Psychological and Behavioral Interventions

• The British Journal of Dermatology suggests using stress reduction techniques, such as cognitive behavioral therapy and habit reversal training, to break the itch-scratch cycle 18, 22
• The American Academy of Dermatology recommends patient support groups, which can be beneficial for patients with chronic pruritus 18, 22

Critical Pitfalls to Avoid

• The British Journal of Dermatology warns against delaying sodium restriction, as this is the most direct intervention for salt-triggered pruritus 18, 19
• The American Academy of Dermatology advises against using sedating antihistamines long-term, due to the risk of dementia, especially in elderly patients, with a strength of recommendation B 18, 19
• The European Association for the Study of the Liver recommends avoiding the use of gabapentin for hepatic pruritus, as it is ineffective 18, 19

Guideline for Evaluation and Management of Generalized Pruritus Without Rash

Epidemiology

Initial Laboratory Workup (All Patients)

Do not perform routine endocrine panels, chest radiographs, or extensive malignancy screens unless specific systemic symptoms are present【23】【24】.

History‑Directed Targeted Testing

Immediate Symptomatic Management (While Awaiting Results)

Cause‑Specific Treatment Algorithms

Iron‑Deficiency Pruritus

Uremic Pruritus

Hepatic/Cholestatic Pruritus

Polycythemia Vera–Associated Pruritus

Lymphoma‑Associated Pruritus

Refractory Systemic Therapies (If No Improvement After 2–4 Weeks)

Referral and Additional Investigations

When to Refer to Dermatology

Specialist Referrals

Further Diagnostic Tests (If Initial Workup Unrevealing)

Key Clinical Pitfalls (Supported by Evidence)

Evidence‑Based Evaluation of Lower Extremity Pruritus in Adults

Systemic Causes

• Systemic diseases should be excluded via targeted laboratory testing in adults with lower‑extremity pruritus. 26
• Chronic kidney disease and uremia are established causes of pruritus, with severity correlating with disease stage. 26
• Hepatitis A, B, C, and E infections can cause generalized pruritus. 26, 27
• Solid tumors may present with paraneoplastic pruritus. 26

Medication‑Induced Pruritus

• Comprehensive review of over‑the‑counter and herbal medications is essential because drug‑induced pruritus is a notable cause. 26, 28
• A thorough medication history, including OTC and herbal products, is critical because drug‑induced pruritus is common and reversible. 26, 28

Infectious and Parasitic Causes

• Scabies can cause severe pruritus with minimal skin findings, especially in immunocompromised patients. 26, 27
• HIV infection is associated with pruritus, correlating with viral load and may appear at any disease stage. 26, 27, 28
• Parasitic infections such as Strongyloides stercoralis and schistosome species can present with pruritus. 26, 27, 28
• Post‑herpetic pruritus may follow varicella‑zoster infection. 26, 27

Psychiatric and Psychogenic Factors

• Psychological conditions (depression, anxiety, obsessive‑compulsive disorder) are frequently observed in patients with chronic pruritus. 26, 28
• Substance abuse should be considered in the differential diagnosis of chronic pruritus. 26, 28
• Physical causes must be ruled out before attributing pruritus to psychogenic origins. 26, 27, 28

Clinical Pitfalls

• Scabies should be considered even when skin signs are minimal, particularly in immunocompromised or HIV‑positive individuals. 26, 27

Guideline Summary for Chronic Pruritus Management

Etiology & Classification

• Pruritus without visible skin lesions can be classified into four major groups: systemic disease‑related (≈15 %), neuropathic (≈25 %), inflammatory (≈60 %), and generalized pruritus of unknown origin (GPUO) 29.
• Systemic cholestatic liver disease typically presents with palm/sole predominance and nocturnal worsening 29.
• Chronic kidney disease/uremia‑related pruritus correlates with the severity of renal impairment and is a well‑established cause 29.
• Hematologic disorders—including polycythemia vera (aquagenic pruritus), Hodgkin’s lymphoma, and solid tumors—are recognized systemic triggers 29.
• Drug‑induced pruritus accounts for about 12.5 % of adverse drug reactions, especially with opioid use 29.
• Endocrine disorders (thyroid disease, diabetes) and infections such as HIV or hepatitis can also provoke pruritus 29.

Diagnostic Workup

Mandatory Initial Laboratory Panel (all patients with chronic generalized pruritus and no rash)

• Complete blood count with differential to screen for polycythemia vera, lymphoma, and anemia 29.
• Comprehensive iron studies (serum iron, ferritin, transferrin saturation) – ferritin alone is insufficient 29.
• Liver function tests, total bilirubin, and serum bile acids to identify cholestatic disease 29.
• Renal panel (urea, creatinine, electrolytes) to detect uremic pruritus 29.

History‑Driven Conditional Tests

• Thyroid‑stimulating hormone when clinical features suggest thyroid dysfunction 29.
• JAK2 V617F mutation testing if aquagenic pruritus raises suspicion for polycythemia vera 29.
• HIV and hepatitis A‑B‑C serologies in patients with relevant travel or risk factors 29.

Second‑Tier Investigations (if initial workup unrevealing)

• Skin biopsy for persistent unexplained pruritus to evaluate cutaneous lymphoma or small‑fiber neuropathy 29.

First‑Line Management (All Patients)

• Liberal use of emollients/moisturizers at least twice daily while awaiting diagnostic results 29, 30.
• High‑lipid moisturizers are especially beneficial in elderly patients 31.
• Self‑care counseling – keep nails short, avoid hot water, and employ stress‑reduction techniques 31.
• Non‑sedating antihistamines (e.g., fexofenadine 180 mg or loratadine 10 mg daily) for symptomatic relief while investigations proceed 29, 30.
• If sleep is disrupted, a mildly sedating antihistamine such as cetirizine 10 mg may be used 29, 30.

Cause‑Specific Treatment Algorithms

Uremic (Chronic Kidney Disease) Pruritus

• First‑line: Broadband UVB phototherapy – the most effective therapy (Level 1+ evidence) 29.
• Optimize dialysis adequacy (Kt/V ≥ 1.6) to relieve pruritus in ≈ 40 % of patients 29.
• Second‑line systemic: Gabapentin 300–1200 mg daily in divided doses 29.

Cholestatic/Hepatic Pruritus

• First‑line: Rifampin 150 mg twice daily (Strength A) 29, 30.
• Second‑line: Cholestyramine 9 g daily 29, 30.
• Third‑line: Sertraline 29, 30.
• Fourth‑line: Naltrexone or nalmefene 29, 30.
• Fifth‑line options: Dronabinol, phenobarbital, propofol, or topical tacrolimus 29, 30.
• Phototherapy (broadband UVB or combined UVA/UVB) may also alleviate cholestatic itch 29, 30.

Drug‑Induced Pruritus

• Opioid‑related: Naltrexone is the first‑choice when opioid continuation is unavoidable (Strength B) 29, 30; alternatives include methylnaltrexone, ondansetron, droperidol, mirtazapine, and gabapentin 29, 30.
• Post‑operative: Rectal diclofenac 100 mg 29, 30.
• Chloroquine‑related: Prednisolone 10 mg, niacin 50 mg, or their combination; dapsone is an alternative 29, 30.

Neuropathic Pruritus

• Topical agents such as menthol, pramoxine, or lidocaine (alone or combined with topical steroids) 29, 30.
• Systemic gabapentin or pregabalin 29, 30; antidepressants (sertraline, doxepin) may be added 29, 30.
• Referral to neurology or pain‑management specialists for refractory cases 29, 30.

Psychogenic Pruritus

• Behavioral interventions—education, trigger avoidance, relaxation techniques, cognitive restructuring, habit‑reversal training—are recommended 29, 30.
• Support groups and referral to social workers, liaison psychiatry, or psychologists are advised 29, 30.
• Narrow‑band UVB phototherapy may provide adjunctive benefit 29, 30.

Refractory Pruritus (Second‑Line Systemic Therapies)

• Antidepressants (paroxetine, fluvoxamine, mirtazapine) 29, 30.
• Neuropathic agents (gabapentin or pregabalin) – avoid in hepatic disease 29, 30.
• Opioid antagonists (naltrexone, butorphanol) 29, 30.
• Anti‑emetics (ondansetron, aprepitant) 29, 30.
• Combined H1/H2 blockade (fexofenadine + cimetidine) 29, 30.

Age‑Specific Considerations (Patients > 65 years)

• Initiate emollients and low‑potency topical steroids for ≥ 2 weeks to rule out asteatotic eczema 31.
• Use high‑lipid moisturizers to address age‑related barrier dysfunction 31.
• Consider gabapentin if neuropathic components are suspected 31.
• Avoid long‑term sedating antihistamines due to increased dementia risk 31.
• Suspect bullous pemphigoid when pruritus precedes blister formation; obtain skin biopsy and indirect immunofluorescence 31.

Referral Criteria

• Dermatology referral for persistent pruritus > 2–4 weeks despite first‑line therapy or when diagnostic uncertainty remains 29, 30.
• Hepatology referral for significant hepatic impairment or persistent cholestatic enzyme elevation.
• Nephrology referral for elevated creatinine requiring dialysis optimization.
• Hematology referral when polycythemia vera is suspected (elevated hemoglobin/hematocrit with positive JAK2 mutation).

Primary Care Management Algorithm

• Day 1 – Immediate actions: Apply emollients twice daily, provide self‑care counseling, and order the mandatory laboratory panel 31, 29.
• While awaiting results: Trial non‑sedating antihistamines; consider topical menthol or clobetasone butyrate for symptomatic relief 29, 30.
• Follow‑up: Review lab results, initiate cause‑specific therapy if an etiology is identified, and schedule regular reassessment for unexplained cases 31.
• If no improvement after 2–4 weeks: Refer to secondary care (dermatology, hepatology, nephrology, or appropriate specialty) 29, 30.

Guideline for Evaluation and Management of Chronic Burning Pruritus

1. Etiology and Clinical Presentation

• Chronic pruritus with a painful burning quality most commonly reflects neuropathic pruritus (e.g., small‑fiber neuropathy, post‑herpetic neuralgia, nerve‑compression syndromes) and requires systematic exclusion of systemic causes such as cholestatic liver disease, uremic pruritus, and iron deficiency. 32
• Small‑fiber neuropathy is the leading cause of burning pruritus, arising from damage to unmyelinated C‑fibers that transmit both pain and itch signals. 32
• Diabetic neuropathy may present as generalized or localized burning pruritus, particularly affecting the lower extremities. 32
• Cholestatic pruritus typically involves the palms and soles, worsens at night, and has a burning quality due to bile‑acid–mediated activation of itch and pain receptors. [32][33]
• Serum bile‑acid measurement is the definitive diagnostic test for cholestatic pruritus and should be ordered promptly together with liver function tests and total bilirubin. 32
• Routine assessment of urea, creatinine, and electrolytes is essential in any patient with unexplained burning pruritus to identify possible uremic contributors. 32
• Iron deficiency can cause generalized pruritus with a burning component and accounts for roughly one‑quarter of systemic‑disease‑related pruritus cases. 32
• Iron replacement therapy results in complete resolution of pruritus within days to weeks after initiation. 32
• In patients with aquagenic pruritus suggestive of polycythemia vera, testing for the JAK2 V617F mutation is recommended. 32

2. Recommended Initial Laboratory Workup

• Obtain a complete blood count with differential (to screen for polycythemia vera, lymphoma, anemia). 32
• Perform comprehensive iron studies (serum iron, ferritin, transferrin saturation). 32
• Order liver function tests, total bilirubin, and serum bile‑acid levels. 32
• Conduct a renal panel including urea, creatinine, and electrolytes. 32
• Measure fasting glucose and hemoglobin A1c to evaluate for diabetic neuropathy. 32
• Check thyroid‑stimulating hormone when clinical features suggest thyroid dysfunction. 32

3. History‑Directed Additional Testing

• HIV and hepatitis A, B, C serologies should be obtained when epidemiologic risk factors are present. 32
• Skin biopsy is indicated for persistent, unexplained cases to assess for cutaneous lymphoma or small‑fiber neuropathy (e.g., reduced intra‑epidermal nerve‑fiber density). 32
• Antimitochondrial antibody testing is warranted when cholestatic liver tests raise suspicion for primary biliary cholangitis. 32

4. Symptomatic Management While Awaiting Diagnostic Results

• Apply emollients liberally at least twice daily to mitigate xerosis, which lowers the threshold for both itch and pain perception. 32

5. Cause‑Specific Therapeutic Algorithms

Neuropathic Pruritus

• First‑line systemic therapy: gabapentin 300 mg at bedtime, titrated to 300–1200 mg daily in divided doses over 1–2 weeks based on response and tolerability. 32

Cholestatic Pruritus

• (Diagnostic step) Confirm elevated serum bile acids before initiating targeted therapy. 32

Iron‑Deficiency‑Related Pruritus

• Oral iron replacement (e.g., ferrous sulfate 325 mg daily or equivalent elemental iron 65 mg daily) leads to complete cessation of pruritus within days to weeks. 32

6. Referral Recommendations

• Refer to dermatology if pruritus persists >2–4 weeks despite first‑line therapy or if diagnostic uncertainty remains. 32
• Refer to neurology for refractory neuropathic pruritus requiring advanced pain‑management techniques or when small‑fiber neuropathy is confirmed on biopsy. 32
• Refer to hepatology for significant hepatic impairment (elevated transaminases >3 × upper limit of normal, elevated bilirubin, or elevated bile acids). 32
• Refer to nephrology for elevated creatinine necessitating dialysis optimization or consideration of renal replacement therapy. 32

Neuropathic Pruritus and Small‑Fiber Neuropathy

Diagnosis

• The presence of chronic itch together with a burning, stinging or tingling sensation, even when routine laboratory and electrophysiological studies are normal, most strongly points to neuropathic pruritus, particularly small‑fiber neuropathy. 34
• Burning‑type pruritus reflects damage to unmyelinated C‑fibers that convey both pain and itch signals, distinguishing it from systemic inflammatory or histamine‑mediated itch. 34

Common Underlying Neuropathic Conditions

• Diabetes mellitus can produce regional burning pruritus of the trunk or lower limbs through diabetic small‑fiber neuropathy. 34
• Localized nerve‑compression syndromes (e.g., brachioradial pruritus, notalgia paraesthetica) generate pruritus confined to specific dermatomes. 34
• Systemic illnesses such as HIV infection, sarcoidosis, Guillain‑Barré syndrome, and neurofibromatosis type 1 are recognized triggers of small‑fiber neuropathy‑related itch. 34

Essential Diagnostic Work‑up

• Comprehensive iron panel (serum iron, ferritin, transferrin saturation) should be ordered because ferritin alone may be falsely normal in the setting of inflammation. 35
• Renal function panel (urea, creatinine, electrolytes) is required to rule out uremic pruritus. 34
• Skin biopsy with quantification of intra‑epidermal nerve‑fiber density is the definitive test for confirming small‑fiber neuropathy when clinical suspicion is high and routine tests are unrevealing. 34

First‑Line Pharmacologic Management

• Gabapentin is the preferred systemic agent for neuropathic pruritus with a burning quality; dosing typically starts at 300 mg at night and is titrated to 300–1200 mg daily based on response and tolerability. 34

Cause‑Specific Therapies

Psychogenic (Functional) Pruritus – Diagnosis of Exclusion

• Must meet all three compulsory criteria: chronic itch > 6 weeks, no identifiable somatic cause after thorough investigation, and a generalized distribution. 34
• At least three of seven optional criteria (e.g., temporal relation to stress, nocturnal worsening, predominance at rest, associated mood disorder, response to psychotropic medication or psychotherapy) support the diagnosis. 34
• Behavioral interventions—patient education, trigger avoidance, relaxation techniques, cognitive restructuring, and habit‑reversal training—are the cornerstone of management. 34

Clinical Pearls

• A burning quality of itch is a red flag for neuropathic mechanisms and should prompt gabapentin therapy rather than antihistamines. 34
• “Negative” laboratory results often reflect incomplete testing; ensure that iron studies, bile acids, and glucose/HbA1c have been performed. 35
• Skin biopsy remains the only test that can definitively demonstrate small‑fiber neuropathy in patients with normal routine labs and electrophysiology. 34
• Iron replacement yields rapid symptom relief (days to weeks) when deficiency is the underlying driver, making it both diagnostic and therapeutic. 35

Guideline for Evaluation and Management of Chronic Pruritus with Lichenification

Diagnostic Workup

• Order a complete blood count with differential to screen for polycythemia vera, lymphoma, and occult anemia in patients with chronic pruritus. 37
• Include liver function tests, total bilirubin, and serum bile acids to detect cholestatic disease, which often presents with palm‑/sole‑predominant itch that worsens at night. 37
• Perform a renal panel (urea, creatinine, electrolytes) to identify uremic pruritus. 37
• Measure thyroid‑stimulating hormone when clinical features suggest thyroid dysfunction. 37
• Test for the JAK2 V617F mutation in patients reporting aquagenic pruritus, as a positive result is pathognomonic for polycythemia vera. 37
• Obtain HIV and hepatitis A, B, C serologies in individuals with relevant risk factors or travel history. 37
• Conduct a skin biopsy for persistent, unexplained pruritus to evaluate for cutaneous lymphoma or small‑fiber neuropathy (reduced intra‑epidermal nerve‑fiber density). 37

First‑Line Symptomatic Management

• Apply high‑lipid emollients liberally at least twice daily to all affected areas; this universal measure restores skin barrier function and reduces itch threshold. 37
• Use topical menthol 1–3 % or pramoxine 1 % for rapid cooling relief of acute itch. 38
• Apply a low‑potency topical corticosteroid (e.g., clobetasone butyrate 0.05 %) for two weeks to treat underlying asteatotic eczema contributing to lichenification. 37
• Initiate gabapentin as the first‑line systemic agent for neuropathic pruritus associated with chronic scratching‑induced nerve damage; start 300 mg at bedtime and titrate to 300–1200 mg daily based on response. 37
• Avoid long‑term use of sedating antihistamines in elderly patients because of an increased risk of dementia (Strength B). 37
• Offer non‑sedating antihistamines (e.g., fexofenadine 180 mg or loratadine 10 mg daily) for modest symptomatic relief, recognizing they are generally ineffective for systemic causes. 37

Cause‑Specific Treatment Algorithms

Iron‑Deficiency Pruritus

• Provide oral iron replacement (e.g., ferrous sulfate 325 mg daily) which can lead to complete cessation of itch within days to weeks. 37

Cholestatic Liver Disease

• First‑line: Rifampin 150 mg twice daily (Strength A). 37
• Second‑line: Cholestyramine 9 g daily. 37
• Third‑line: Sertraline 75–100 mg daily. 37
• Contraindication: Do not use gabapentin for hepatic pruritus; it is ineffective and potentially harmful. 37

Uremic Pruritus

• Employ broadband UVB phototherapy, the most effective therapy (Level 1+ evidence). 37
• Continue gabapentin 300–1200 mg daily as an adjunctive systemic agent. 37

Polycythemia Vera (JAK2‑Positive)

• Low‑dose aspirin 81 mg daily provides immediate itch relief. 39
• Paroxetine yields >80 % response rates in this population. 39
• Interferon‑α reduces pruritus in up to 81 % of refractory cases. 39

Small‑Fiber Neuropathy (Biopsy‑Confirmed)

• Maintain gabapentin 300–1200 mg daily as primary therapy. 37
• Add topical lidocaine 5 % or capsaicin 0.025–0.1 % to lichenified areas for additional relief.
• Consider pregabalin if gabapentin is ineffective. 37

Behavioral Interventions to Disrupt the Itch‑Scratch Cycle

• Implement habit‑reversal training (e.g., substituting scratching with fist‑clenching, pressure, or ice packs). 37
• Keep nails trimmed short and use cotton gloves at night to minimize mechanical damage. 38
• Advise lukewarm showers only; avoid hot water that aggravates itch. 38
• Apply stress‑reduction techniques such as cognitive‑behavioral therapy or relaxation exercises. 37
• Encourage participation in patient support groups for psychosocial support. 37

Referral Criteria

• Refer to dermatology if pruritus persists >2–4 weeks despite first‑line therapy. 37
• Refer to dermatology when diagnostic uncertainty remains after the initial workup. 37
• Refer to dermatology if lichenification progresses despite appropriate treatment. 40

Critical Pitfalls to Avoid

• Do not accept “normal iron studies” without confirming that serum iron, ferritin, and transferrin saturation were measured; ferritin alone can be falsely normal in inflammatory states. 37
• Recognize that antihistamines alone are ineffective for cholestatic, uremic, or neuropathic pruritus. 37
• Avoid long‑term sedating antihistamines due to dementia risk (Strength B). 37
• Do not use gabapentin for hepatic pruritus; it offers no benefit and may be harmful. 37